

Remarks

The specification is amended to correct certain typographical errors.

Claims 1, 5, 19, 30, and 41-42 are pending in this application. Claim 41 is amended to correct typographical errors, and to remove its dependency from claim 5. No new matter has been added.

Applicants appreciate the Examiner's withdrawal of certain rejections previously outstanding under 35 U.S.C. §112. In addition, Applicants respectfully submit that all of the pending claims are allowable for at least the following reasons.

A. The Objection to the Disclosure Should Be Withdrawn

On page 3 of the Office Action, the disclosure of this application is objected to because the amendment contains a typographical error, *i.e.*, an unnecessary period exists before a semicolon. Accordingly, Applicants present a further amendment herein in which the period has been removed. In view of this submission, Applicants respectfully request that the objection of the disclosure be withdrawn.

B. The Rejections Under 35 U.S.C. § 112 Should Be Withdrawn

On page 2 of the Office Action, the rejection of claim 41 under 35 U.S.C. § 112, as allegedly indefinite, is maintained. This rejection is based on the fact that one of the chemical compound recited by claim 41, which depended from claim 1 or claim 5, was not within the scope of claim 5. In this regard, claim 41 is amended herein to remove its dependency from claim 5. In view of this amendment, Applicants respectfully request that this rejection be withdrawn.

On pages 3-4 of the Office Action, claim 41 is further rejected as allegedly failing to comply with the written description requirement and being indefinite. In particular, the rejection appears to stem from the claim's recitation of the term "indolin" instead of "isoindoline" for the first four species recited by the claim. As these typographical errors were corrected by the amendments presented herein,¹ Applicants respectfully request that the rejection be withdrawn.

¹ In addition, Applicants respectfully point out that these amendments do not result in the addition of new matters. (*See, e.g.*, specification, page 28, lines 3-7).


Conclusion

In view of the foregoing, Applicants respectfully submit that all of the pending claims are allowable.

No fee is believed due for the submission of this paper. If any fees are required for the submission of this paper, or to avoid abandonment of this application, please charge such fees to Jones Day Deposit Account No. 503013.

Date: March 21, 2007

Respectfully submitted,



Hoon Chol (Ltd. Recog. No. L0209)
JONES DAY

for: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
12265 El Camino Real, Suite 200
San Diego, CA 92130
(858) 314-1200